Lupin Limited has scored a major global milestone with the U.S. FDA clearing its new product Armlupeg™, a biosimilar version of Neulasta (pegfilgrastim) used widely in cancer care. The approval covers the 6 mg/0.6 mL injection in a single-dose prefilled syringe intended for subcutaneous use, opening a fresh pathway for Lupin in the high-value U.S. oncology support market.
The drug will be manufactured at Lupin’s biotech facility in Pune, a site that recently underwent a successful FDA inspection. With this approval, Lupin strengthens its position in the global biosimilars space, especially in categories where demand remains consistently strong due to rising cancer treatment volumes.
Armlupeg™ is designed to help lower the risk of infection caused by febrile neutropenia in patients receiving myelosuppressive chemotherapy for non-myeloid cancers. It is also approved to improve survival in individuals exposed to high levels of radiation that can severely suppress bone marrow function. Pegfilgrastim products like Neulasta are widely used to promote white blood cell recovery, making them essential supportive therapies in oncology.
The market opportunity is significant. Pegfilgrastim 6 mg/0.6 mL injections recorded estimated annual U.S. sales of around USD 1.29 billion for the twelve months ending September 2025, based on IQVIA data. With Armlupeg™, Lupin enters a competitive but high-reward market where biosimilar adoption continues to rise due to cost efficiencies and expanded treatment access.